Stocktoria
Entera Bio Ltd. ENTX
Entera Bio Ltd. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($1.26); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
P / E vs its own history
Entera Bio Ltd. trades at about 11.2× earnings — above its 10-year norm (10-year range 2×–8.8×, median 4.9×).
Shaded band = 10-year range (2×–8.8×); dot = today's 11.2×.
Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Gross margin | 0.0% | 5.0% | — | 24.6% | 34.7% | 17.8% |
| Operating margin | -27450.0% | -5295.6% | — | -9714.2% | -2139.6% | -3059.7% |
| Net margin | -27235.7% | -5271.3% | — | -9754.5% | -2134.3% | -3072.9% |
| FCF margin | -17802.4% | -3768.5% | — | -9362.7% | -1590.2% | -2906.8% |
| Return on assets | -71.5% | -101.6% | -75.6% | -99.6% | -46.9% | -115.4% |
| Return on equity | -87.3% | -118.1% | -85.6% | -111.2% | -54.0% | -149.3% |
| Current ratio | 6.94 | 7.63 | 10.32 | 9.58 | 8.01 | 4.95 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.